Mesoblast Ltd has released a press release.
Update on BLA for Graft Versus Host Disease
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Mesoblast
- MSB Reports Q3 Financial Results and Operational Highlights
- Third Quarter Financial Results on Form 6-K
- Reinstatement to Official Quotation
- Mesoblast Completes Private Placement
- Voluntary Suspension
Later from Mesoblast
- MSB Launches Entitlement Offer and Placement
- Entitlement Offer and Placement Investor Presentation
- Mesoblast Completes Institutional Allocation
- Information For Retail Shareholders
- FDA Grants Rare Pediatric Disease Designation for Revascor
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast